Quipt Home Medical (QIPT) AI Stock Analysis

• Market Cap: C$149.01M
• Dividend Yield: N/A
• Average Volume (3M): 17.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: -0.70%
• EPS Growth: -102.48%
• Country: CA
• Employees: 1,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 43,443,974
• 10 Day Avg. Volume: 13,933
• 30 Day Avg. Volume: 17,639
• PEG Ratio: -0.15
• Price to Book (P/B): 1.15
• Price to Sales (P/S): 0.50
• P/FCF Ratio: 4.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$5.18
• Price Target Upside: 50.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 48 Neutral
• Price Target: C$3.50 ▲(1.45% Upside)

Quipt Home Medical's overall stock score reflects significant challenges in financial performance and valuation, primarily due to declining profitability and a negative P/E ratio. Technical analysis indicates bearish conditions, though there is potential for a rebound. The earnings call provided some positive insights into strategic growth initiatives, but ongoing financial challenges weigh heavily on the score.

Positive Factors

Strategic Partnerships

Strategic partnerships with major health systems expand Quipt's geographical reach and service offerings, enhancing market position and driving long-term growth.

Recurring Revenue

A high percentage of recurring revenue provides a stable and predictable income stream, supporting financial stability and long-term planning.

Joint Venture with Hart Medical

The joint venture with Hart Medical Equipment enhances Quipt's scale and revenue base, contributing to operational efficiency and market expansion.

Negative Factors

Declining Revenue

A year-over-year decline in revenue indicates challenges in maintaining market share and could impact long-term financial performance if not addressed.

Increased Operating Expenses

Rising operating expenses can erode profit margins and reduce financial flexibility, posing a risk to long-term profitability if not controlled.

Net Loss Increase

An increasing net loss highlights ongoing profitability issues, which can strain resources and hinder investment in growth initiatives.

Quipt Home Medical Business Overview & Revenue Model

Company Description

Quipt Home Medical (QIPT) is a leading provider of in-home monitoring and disease management services, offering a comprehensive range of products and services to support patients with chronic illnesses. Operating primarily in the healthcare sector, Quipt Home Medical specializes in providing durable medical equipment (DME) such as respiratory devices, sleep apnea equipment, and mobility aids. The company is dedicated to improving the quality of life for patients by facilitating effective home-based healthcare solutions.

How the Company Makes Money

Quipt Home Medical makes money through the sale and rental of durable medical equipment (DME) and the provision of related healthcare services. The company's key revenue streams include insurance reimbursements from government and private health insurers, direct sales to patients, and rental income from equipment provided to patients on a temporary basis. Significant factors contributing to its earnings include the growing demand for home-based healthcare solutions, strategic partnerships with healthcare providers, and a focus on expanding its service offerings and geographical reach to meet the needs of an aging population.

Quipt Home Medical Financial Statement Overview

Summary

Quipt Home Medical shows strong revenue growth and solid cash flow management, but struggles with net profitability and rising liabilities. The company's financial health is supported by consistent operational cash flow, indicating potential for improved profitability with strategic adjustments.

Income Statement

Quipt Home Medical has demonstrated consistent revenue growth, with a revenue increase from $221.74 million in 2023 to $241.93 million in TTM 2024, highlighting positive sales momentum. However, despite growing revenues and gross profit margins (71.6% in TTM 2024), profitability remains a challenge, as indicated by negative net income margins (-3% in TTM 2024). The EBIT margin is marginally positive, suggesting minimal operational profitability.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.95 in TTM 2024, reflecting balanced leverage. However, the return on equity is concerning due to negative net income, affecting shareholder returns. The equity ratio remains stable at approximately 43.8%, indicating a sound capital structure but with limited financial flexibility due to rising liabilities.

Cash Flow

Quipt Home Medical exhibits robust cash flow management, with a healthy free cash flow of $20.52 million in TTM 2024. The operating cash flow to net income ratio is strong, showcasing effective cash generation from operations despite net losses. Free cash flow growth has been variable, but the company maintains a solid cash position to support future investments and operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	229.68M	245.91M	211.68M	139.86M	102.35M	72.64M
Gross Profit	164.24M	176.99M	153.78M	106.65M	74.18M	52.70M
EBITDA	48.06M	51.07M	44.07M	28.05M	13.21M	12.80M
Net Income	-10.26M	-6.76M	-2.78M	4.84M	-6.17M	-4.57M
Balance Sheet
Total Assets	236.09M	247.25M	247.41M	132.21M	108.57M	53.95M
Cash, Cash Equivalents and Short-Term Investments	11.25M	16.17M	17.21M	8.52M	34.61M	21.88M
Total Debt	92.35M	99.80M	97.96M	10.93M	27.05M	17.17M
Total Liabilities	133.56M	140.06M	136.29M	52.67M	49.95M	32.81M
Stockholders Equity	102.54M	107.19M	111.11M	79.55M	58.62M	21.14M
Cash Flow
Free Cash Flow	20.66M	25.07M	33.75M	17.38M	13.65M	―
Operating Cash Flow	34.65M	35.38M	40.54M	26.34M	18.69M	―
Investing Cash Flow	-12.97M	-10.31M	-82.83M	-42.49M	-17.84M	―
Financing Cash Flow	-24.79M	-26.15M	50.87M	-9.85M	3.91M	10.48M

Quipt Home Medical Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.45
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:QIPT, the sentiment is Neutral. The current price of 3.45 is below the 20-day moving average (MA) of 3.62, below the 50-day MA of 3.45, and above the 200-day MA of 3.30, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.86 is Neutral, neither overbought nor oversold. The STOCH value of 39.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:QIPT.

Quipt Home Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRN	54 Neutral	C$232.61M	―	-106.37%	―	64.42%	-21.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QIPT	48 Neutral	C$149.01M	―	-9.96%	―	-0.70%	-102.48%
PINK	45 Neutral	C$28.51M	―	-233.44%	―	219.12%	-15.92%
VPT	44 Neutral	C$17.61M	―	207.08%	―	88.47%	11.88%
TLT	44 Neutral	C$50.13M	―	-291.69%	―	16.00%	9.79%
ASG	42 Neutral	C$23.81M	―	-26.27%	―	17.61%	-19.19%

Quipt Home Medical Corporate Events

Quipt Home Medical Expands Midwest Presence Through Strategic Joint Venture

Quipt Home Medical has announced a strategic joint venture with three major health systems, acquiring a 60% stake in Hart Medical Equipment. This move is set to enhance Quipt’s presence in the Midwest, particularly with its entry into the Michigan market, and is expected to add $60 million in revenue. The partnership will strengthen Quipt’s integration with healthcare systems, leveraging Hart’s established relationships with hospitals and care facilities. The transaction is anticipated to close by the end of Fiscal Q4, 2025, and is expected to align with Quipt’s strategic goals of expanding its service network and improving patient care outcomes.

The most recent analyst rating on (TSE:QIPT) stock is a Buy with a C$8.50 price target. To see the full list of analyst forecasts on Quipt Home Medical stock, see the TSE:QIPT Stock Forecast page.

Quipt Home Medical Achieves Positive Growth and Expands Reach with Strategic Acquisition

Quipt Home Medical reported its fiscal third quarter 2025 results, highlighting a return to positive organic growth with a 1.6% increase in quarter-over-quarter revenue, despite a year-over-year decrease. The company achieved an adjusted EBITDA of 23.5% of revenue and maintained strong recurring revenue at 81%. Operationally, Quipt expanded its reach through the acquisition of a durable medical equipment provider, enhancing its presence in the Appalachian Highlands region and securing a Preferred Provider Agreement with Ballad Health. This strategic move is expected to align the acquired operation’s margins with Quipt’s historical range, supporting long-term growth and stability.

The most recent analyst rating on (TSE:QIPT) stock is a Buy with a C$8.50 price target. To see the full list of analyst forecasts on Quipt Home Medical stock, see the TSE:QIPT Stock Forecast page.

Quipt Home Medical to Release Q3 2025 Financial Results

Quipt Home Medical Corp. is set to announce its fiscal third-quarter 2025 financial results on August 11, 2025, with a conference call scheduled for the following day. This announcement is significant as it provides insights into the company’s financial health and operational progress, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (TSE:QIPT) stock is a Buy with a C$8.50 price target. To see the full list of analyst forecasts on Quipt Home Medical stock, see the TSE:QIPT Stock Forecast page.